A Mab A Case Study In Bioprocess Development ((top)) Jun 2026

The paper outlines the "lab bench to bedside" journey through four primary phases: A–Mab: A Case Study in Bioprocess Development - ISPE

To establish a robust, scalable, and compliant manufacturing process ensuring high product purity (>98% monomer) and consistency.

The process remained stable even with minor variations in raw materials. Key Takeaway:

If upstream is about growing the protein, downstream is about catching it and cleaning it. This is often the most expensive phase of production due to the high cost of resins and chromatography columns. A Mab A Case Study In Bioprocess Development

After capture, the eluate undergoes , typically using a low pH hold, which destroys enveloped viruses. Finally, two polishing chromatography steps are performed—anion exchange (AEX) and cation exchange (CEX)—to remove residual HCPs, DNA, and aggregated forms of the mAb. The entire chromatography process is itself optimized through the application of Analytical Quality by Design (AQbD) . For example, when a previous Protein-A HPLC method for titer quantitation proved unreliable, retrospective application of AQbD principles identified a bias from standard vial materials. By re-optimizing the method, the team reduced development timelines for new products by 50% and gained more accurate titer data.

The bioprocess pipeline for mAb A begins with the . The QTPP outlines the clinical performance goals, dosage requirements, and safety standards for the drug.

If you want, I can:

Development begins with the Target Product Profile (TPP) , which outlines the desired clinical performance. The study identified key attributes that must be controlled, including:

Process characterization involves understanding how various parameters affect these quality attributes. This is often done using a approach to efficiently study multiple variables at once.

A detailed breakdown of a (like Protein A chromatography). The paper outlines the "lab bench to bedside"

A Mab’s high concentration (20 g/L intermediate) posed a challenge. Standard 20 nm filters fouled rapidly. The solution: with pre-filtration using 0.1 µm and operation at constant pressure (2 bar). Flux dropped only 30% over 4 hours, acceptable for GMP.

The step achieved a turbidity reduction to < 10 NTU and a step yield of 92%, protecting the downstream Protein A column from fouling. 3. Downstream Processing: Purification and Safety Assurance

During scale-up, an increase in acidic charge variants was observed in the 2,000 L bioreactor. Trace element analysis revealed that higher copper concentrations in the large-scale media accelerated basic variant conversion. Adjusting the copper supplementation down by 15% successfully realigned the charge variant profile with the clinical reference standard. 5. Conclusion and Key Takeaways This is often the most expensive phase of

The bioprocess for A Mab was developed and optimized through a series of experiments and studies. The process involved the following steps:

A process that works beautifully at a 2 L bench-top bioreactor may fail at a 2,000 L commercial scale. Small deviations in mixing, oxygen transfer, or heat dissipation can dramatically alter cell behavior and product quality. The key to successful is maintaining geometric, hydrodynamic, and mass-transfer similarity across scales.